Cingulate Inc. (CING)
NASDAQ: CING · IEX Real-Time Price · USD
0.802
+0.012 (1.51%)
At close: May 17, 2024, 3:59 PM
0.819
+0.017 (2.14%)
After-hours: May 17, 2024, 5:56 PM EDT
Company Description
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States.
The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.
It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Cingulate Inc.
| Country | United States |
| Founded | 2012 |
| IPO Date | Dec 8, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Dr. Shane J. Schaffer Pharm.D., PharmD |
Contact Details
Address: 1901 W. 47th Place Kansas City, Kansas 66205 United States | |
| Phone | (913) 942-2300 |
| Website | cingulate.com |
Stock Details
| Ticker Symbol | CING |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 0001862150 |
| CUSIP Number | 17248W105 |
| ISIN Number | US17248W2044 |
| Employer ID | 86-3825535 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shane J. Schaffer Pharm.D., PharmD | Chief Executive Officer and Chairman of the Board |
| Dr. Laurie A. Myers M.B.A., Ph.D. | Executive Vice President and Chief Operating Officer |
| Dr. Matthew N. Brams M.D. | Executive Vice President and Chief Medical Officer |
| Jennifer L. Callahan CPA | Senior Vice President and Chief Financial Officer |
| Dr. Raul R. Silva M.D. | Executive Vice President and Chief Science Officer |
| Thomas Dalton | Vice President of Investor and Public Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 17, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| May 13, 2024 | 8-K | Current Report |
| May 8, 2024 | 10-Q | Quarterly Report |
| May 8, 2024 | 8-K | Current Report |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 12, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 4, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 3, 2024 | 424B4 | Prospectus |